Dec 06, 2023 / 12:30PM GMT
Operator
Ladies and gentlemen, thank you for standing by, and welcome to the Arvinas's SABCS data presentation. (Operator Instructions) Again, please be advised that today's conference is being recorded. I would like now to turn the conference over to Jeff Boyle, Vice President of Investor Relations. Please go ahead.
Jeff Boyle Arvinas Inc-IR
Good morning, everyone, and thank you for joining us to discuss this program update for vepdegestrant, which includes a review of two posters that will be presented at San Antonio Breast Cancer Symposium, as well as an update on the development plan to vepdegestrant. Yesterday, we issued a press release highlighting this information which can be accessed in the Investor section of our website at arvinas.com.
With me today are Arvinas's President and Chief Executive Officer, John Houston; Arvinas's Chief Medical Officer, Ron Peck; and Pfizer's Vice President, Development Head of the Breast Cancer Franchise, Adam Schayowitz. Ian Taylor, Arvinas's Chief Scientific Officer, will join for the Q&A portion of the call.
Arvinas Inc to Discuss Vepdegestrant (ARV-471) Data Presented at 2023 San Antonio Breast Cancer Symposium and Plans to Expand Vepdegestrant Development Program Call Transcript
Dec 06, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers